Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines

Study Identifier
GMA-BTXC-10-002
CT.gov Identifier
NCT01391299
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Fillers
  • Facial Aesthetics - Toxins
    • Study Drug
  • botulinum toxin Type A
  • Normal Saline
    • Phase
    N/A
    Sex
    Female & Male
    Age
    19+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Moderate to severe forehead lines
    Exclusion Criteria:
    * Current or previous botulinum toxin treatment of any serotype within one year * Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis * Prior facial cosmetic surgery (e.g. prior periorbital surgery, facial lift, brow lift, eyelid lift or eyebrow surgery) * Facial laser or light treatment, microdermabrasion, or superficial peels within 3 months * Oral retinoid therapy within one year

    Protocol Summary

    This study evaluated the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of forehead lines (facial rhytides) when also administered to frown lines (glabellar rhytides).

    Study Locations

    Location
    Status
    Location
    Toronto, Ontario, Canada
    Status
    Not applicable